Metabolic Solutions Development Raises $23.5M in Series D Round
BioWorld Today Contributing Writer
Kalamazoo, Mich.-based Metabolic Solutions Development Co. (MSDC) will use $23.5 million in proceeds from a Series D financing round to push its Type II diabetes drug candidate (MSDC-0160) through Phase IIB trials. Michigan-based Hopen Life Sciences led the investment with follow-on support from Southwest Michigan First Life Science Fund. MSDC has defied a persistent downward trend in the hard-hit Michigan economy by raising nearly $50 million since it was founded in 2006.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST